Oncobesity News Posts

Lupin signs licensing pact with Galenicum Health for injectable Semaglutide
Lupin Atlantis Holdings SA (LAHSA) has entered into a partnership with Galenicum for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist

BellRing Brands (BRBR) Climbs 12% on Protein Market Growth, Ahead of Earnings
We recently published 10 Stocks Breaking Records While Wall Street Bleeds. BellRing Brands Inc. (NYSE:BRBR) was one of the top performers on Tuesday. BellRing jumped

Novo Nordisk Reteams Apple's Long/Hodgman Ad Duo To Tout Ozempic
Justin Long and John Hodgman this time represent, respectively, Novo Nordisk’s original GLP-1, Ozempic, vs. “other GLP-1 products for type 2 diabetes.”

How Employers Can Save $550/Month on GLP-1s: Introducing Vida Self-Pay
What You Should Know – Vida Health has partnered with RxSaveCard to launch Vida Self-Pay, a first-of-its-kind platform that bypasses traditional PBM markups for anti-obesity

Ozempic’s unexpected side effect: saving airlines $580 million a year on fuel
A new financial report claims weight loss drugs like Ozempic and Wegovy could deliver an unexpected beneficiary: the airline industry. According to a study from

CoreAge Rx Expands GLP-1 Access to Support New Year Weight Loss Goals
WICHITA FALLS, Texas, Jan. 20, 2026 /PRNewswire/ — CoreAge Rx, a leading telehealth pharmacy specializing in personalized medication services, today announced a strategic New Year’s

Zaidy’s owner, weight loss doctor introduce product to combat ‘Ozempic face’
Low energy. “Ozempic face.” Feeling like a deflated balloon. They can be the downsides for people on GLP-1s, the increasingly popular drugs that go by

Bariatric surgery beats GLP-1s for type 2 diabetes across income levels, study says – statnews.com
Bariatric surgery beats GLP-1s for type 2 diabetes across income levels, study says statnews.com Northwest Health Offers Seminar about Weight Loss Surgery and GLP-1a greatnews.life Bariatric surgery

Bariatric surgery outpaces GLP-1s for diabetes, SDOH: Study
In a review of 258 patients with Type 2 diabetes who underwent metabolic bariatric surgery or medical and lifestyle interventions, including GLP-1 drugs, surgery was

Is Oral Wegovy a Game Changer for Novo Nordisk?
Key Points Novo Nordisk just launched an oral version of its popular weight-loss therapy, Wegovy. This move might help it make some headway in an

What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026?
Key Points Viking Therapeutics’ stock was volatile in 2025 due to clinical trial results. VK2735’s oral form faced safety concerns but remains promising. Viking could

Weight Loss Drugs Now Account For 1 In 14 Prescriptions, Study Says
Nearly 2.2 million patients were prescribed a GLP-1 RA between January 2019 and December 2025, according to the study.

30 Ways Trump Impacted The World In His First Year
30 Ways Trump Impacted The World In His First Year Authored by Travis Gillmore and Cathy He via The Epoch Times, President Donald Trump used

GLP-1 Receptor Agonist Prescriptions for Adolescents With Obesity and Associated Disparities
This study examines the prescribing of glucagon-like peptide-1 receptor agonists for adolescents with obesity and associated disparities.

SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes
This comparative effectiveness research study examines whether kidney outcomes differ with sodium-glucose cotransporter-2 (SGLT2) inhibitor vs glucagon-like peptide-1 (GLP-1) receptor agonist treatment in individuals with

GLP-1 Drugs Linked With Chronic Cough
People with type 2 diabetes taking glucagon-like peptide-1 (GLP-1) receptor agonists were more likely to develop chronic cough than people using other second-line medications, a

Ozempic Brings Back the ‘Mac vs PC’ Ads for the GLP-1 Era
Novo Nordisk is worried about competition and wants to be seen as the cool kid… by using a 20-year-old ad format.

Stevanato (STVN) Declined Due to Anticipation of Soft Quarter Ahead
Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded

Novo Nordisk Aims to Set Ozempic Apart From Other GLP-1s in New Ad Campaign
The drugmaker is reprising an Apple campaign with Justin Long and John Hodgman to highlight Ozempic’s FDA-approved uses Drugmaker Novo Nordisk is running ads that

GLP-1 Drugs May Help Airlines Shed Some Financial Weight
Ozempic isn’t just slimming waistlines—it may be trimming jet fuel bills, too. A new analysis from financial firm Jefferies estimates that if GLP-1 weight loss

Vida Health Partners with RxSaveCard to Reduce Rising GLP-1 Costs
SAN FRANCISCO–(BUSINESS WIRE)–Vida Health today announced the launch of Vida Self-Pay (Powered by RxSaveCard) to help employers reduce prescription drug costs.

Doctor’s weight gain warning to anyone taking GLP-1 inhibitors
These medications “don’t magically fix weight loss”, he said

Coca-Cola CEO James Quincey: The U.S. consumer continues to be robust
Coca-Cola chairman and CEO James Quincey joins ‘Squawk Box’ to discuss the state of the consumer, impact of tariffs, impact of GLP-1 drugs on the

Will Trump Win Greenland or Lose Europe? Plus. . .
It’s Tuesday, January 20. This is The Front Page, your daily window into the world of The Free Press—and our take on the world at

Dulaglutide Suppresses Copeptin Levels in Euvolaemia
Dulaglutide, a long-acting GLP-1 receptor agonist, can suppress copeptin levels in individuals with euvolaemia, a secondary analysis of two clinical trials shows. Medscape News UK

Study reveals how rapidly weight comes back after quitting obesity medications
Discontinuing the use of GLP-1 weight-loss medications triggers weight regain more than previously thought, a new study suggested. The research, which was published in The

Weight Watchers’ new CMO on the brand’s reinvention, GLP-1 direction and ChatGPT launch – Ad Age
Weight Watchers’ new CMO on the brand’s reinvention, GLP-1 direction and ChatGPT launch Ad Age

Efficacy of Weight‐Lowering Agents on Fat Distribution: A Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials
ABSTRACT Background Pharmacotherapy offers a potential solution for individuals with overweight and obesity to decrease their body weight. However, there is limited knowledge of the

Trump inauguration anniversary: 20 best pictures from the past year
On 20 January 2025, Donald Trump returned to the White House for a second term. It’s been politically divisive and visually rich. 12 months on,

Tolerability and Safety of Concomitant GLP-1 Receptor Agonist and Biologic Therapy: A Retrospective Chart Review
Post Content

Preferences for basal insulin treatments in adults with type 2 diabetes: A discrete choice experiment in France and Spain
Abstract Aim To quantify the relative importance of frequency of administration in basal insulin treatment preferences of people living with type 2 diabetes (T2D) in

What is the ‘GLP-1 halo effect’?
As the GLP-1 trend expands, a ‘halo effect’ is developing. Consumers in families of GLP-1 users are increasingly eating GLP-1-friendly diets. Meanwhile, many non-GLP-1 users

Analog of prolactin-releasing peptide reduces body weight primarily through sustained fatty acid oxidation rather than hypophagia
Although incretin (GLP-1)-based drugs are highly successful for weight loss, there are some limitations to their use. A modified prolactin-releasing peptide, NN501, causes significant weight

Gut enteroendocrine cell activation using a combination of GPR119 and GPR40 agonists results in synergistic hormone secretion in mice and humans
Sebhat et al. present a strategy to mimic bariatric surgery by activating specialized intestinal cells that secrete satiety hormones, including GLP-1. Preclinically, a combination of

A Skeptic’s Guide to Ozempic and Other GLP-1 Agonists
A new compass for the SKEPDOC column. This column was founded by Harriet Hall, MD (1945–2023) who wrote it from 2006 to 2023. In 2026,

Invesco vs. iShares: Which Consumer Staples ETF Is Better for Investors, PBJ or KXI?
Key Points KXI is more globally diversified, with nearly 100 holdings, but has a slightly deeper five-year drawdown than PBJ, and a weaker five-year total

Down 55%, Should You Buy the Dip on Pfizer?
Pfizer (NYSE: PFE) is in the Wall Street doghouse. It is currently viewed as an also-ran in the drug sector, lagging far behind peers like

Medical Roundup #6
Published on January 19, 2026 9:20 PM GMT The main thing to know this time around is that the whole crazy ‘what is causing the

Bariatric surgery beats GLP-1s for type 2 diabetes across income levels, study says
When endocrinologist Mary Elizabeth Patti looks at a patient with type 2 diabetes who could benefit from weight loss, she sees more than body mass

The Ozempic effect: How weight loss drugs are changing the menu at your favorite restaurant
Twelve percent of Americans reportedly take a GLP-1, according to a recent poll